Inflation Reduction Act: Prescription Drug Pricing Reform

The passing of the landmark Inflation Reduction Act (“IRA”) represents a substantial shift in drug pricing, with potential implications across various areas of the law beyond CMS regulatory issues, including antitrust, FDA, litigation, corporate, and investigations.

Covington’s multidisciplinary team has the ability to combine the tremendous strength of our litigation, investigations, and corporate practices with deep knowledge of policy and policymakers, and one of the world’s leading Life Sciences regulatory practices. Our team-based approach and cross-functional experience enable us to create novel solutions to our clients’ toughest problems, successfully try their toughest cases, and deliver commercially practical advice of the highest quality. We have deep experience with the law’s evolution throughout the legislative process and have been working with clients regarding implementation efforts, as well as planning for the future impacts of the IRA on pharmaceutical research and development, litigation, life cycle planning, and beyond.

IRA Task Force Chair

Krista Carver +1 202 662 5197  kcarver@cov.com